A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab
Abstract The phase 2 KNOCKOUT (NCT05283135) study evaluates higher-than-approved doses of risankizumab, an interleukin-23 inhibitor, for treatment of moderate-to-severe plaque psoriasis. Patients received either 300 or 600 mg of risankizumab at Weeks 0, 4, and 16 and were monitored for 100 weeks wit...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Portfolio
2025-12-01
|
| Seri Bilgileri: | Nature Communications |
| Online Erişim: | https://doi.org/10.1038/s41467-025-67475-0 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|